Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-α-2b and IL-2

Journal of Immunotherapy

Volumn 22, Issue 3, 1999, Pages 260-267

  Moltó, Luis ^a   Carballido, Joaquin ^b   Manzano, Luis ^a   Martinez Martin, Belén ^a   Esquivel, Fátima ^a   Chafer, Joan ^a   Olivier, Carlos ^b   Alvarez Mon, Melchor ^a  

^a HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Immunotherapy; Metastatic renal cell carcinoma; Peripheral blood mononuclear cells; Recombinant interferon 2b; Recombinant interleukin 2

Indexed keywords

ALPHA2B INTERFERON; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CYTOTOXICITY TEST; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; MALE; METASTASIS; MONONUCLEAR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION;

AGED; ANTIGENS, CD56; CARCINOMA, RENAL CELL; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; INTERLEUKIN-2; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEPHRECTOMY; RECEPTORS, IGG; T-LYMPHOCYTES;

EID: 0032964059     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199905000-00009     Document Type: Article

References (34)

1. Boring CC, Squires TI, Tong T. Cancer statistics, 1993. CA 1993;43:7-26.
2. Fowler JE. Nephrectomy in metastatic renal cell carcinoma. Urol Clin North Am 1987;4:749-56.
3. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993;20:303-21.
4. Balch CM, Riley LB, Bae YJ, et al. Patterns of tumour-infiltrating lymphocytes in 120 human cancers. Arch Surg 1990;125:200-5.
5. Haas GP, Redman BG, Vasantha KR, Dybal E, Pontes JE, Hillman GG. Immunotherapy for metastatic renal cell cancer: effect on the primary tumor. J Immunother 1993;13:130-5.
6. Toliou T, Stravoravdi P, Polyzonis P, Vakalikos J. Natural killer cell activation after interferon administration in patients with metastatic renal cell carcinoma: an ultrastructural and immunohisto-chemical study. Eur Urol 1996;29:252-6.
7. Fairlamb DJ. Spontaneous regression of metastasis of renal cancer: a report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature. Cancer 1981;47:2102-6.
8. Marcus SG, Choike PL, Reiter R, et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 1993;150:463-6.
9. Sznol M, Clark IW, Smith JW II, et al. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. J Natl Cancer Inst 1992;84:929-37.
10. Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin 2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:863-74.
11. Atzpodien J, Kirchner H, Hanninen EL, et al. European studies of interleukin-2 in metastatic renal cell carcinoma. Semin Oncol 1993;6:22-6.
12. Ellis TM, McKenzie RS, Simons PE, Helfrich BA, Fisher RI. Induction of human lymphokine-activated killer cells by interferon alpha and interferon gamma. J Immunol 1989;143:4282-6.
13. Holan V, Kohno K, Minowada J. Natural human interferon alpha augments interleukin-2 production by a direct action on the activated interleukin-2-producing T cells. J Interferon Res 1991;11:319-25.
14. Morgan DA, Ruscetti FW, Gallo RC. Selective in vitro growth of T lymphocytes from normal human bone marrow. Science 1976;193:1007-8.
15. Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med 1984;160:1147-69.
16. Lotze MT, Grimm EA, Mazumder EA, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumour by human lymphocytes cultured in T-cell growth factor. Cancer Res 1981;41:4420-5.
17. Schmidt Pak A, Ip G, Wright MA, Young RI. Treating tumour-bearing mice with low-dose -γ-interferon plus tumour necrosis factor-a to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy. Cancer Res 1995;55:885-90.
18. Wanebo H, Pace R, Hargett S, Katz D, Sando J. Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients. Cancer 1986;57:656-62.
19. Dupere S, Obiri N, Lackey A, et al. Patterns of cytokines released by peripheral blood leukocytes of normal donors and cancer patients during interleukin-2 activation in vivo. J Biol Response Mod 1990;9:140-8.
20. Pislarasu M, Oproiv A, Taranu D, Herberman RB, Sulica A. Modulation of natural killer cell activity by serum from cancer patients: preliminary results of a study of patients with colorectal adenocarcinoma or other types of cancer. Cancer Res 1988;48:2596-603.
21. Von Roen J, Harris JE, Braun DP. Suppressor cell function in solid tumor cancer patients. J Clin Oncol 1987;5:150-9.
22. Bukowski RM, Olencki T, Wang Q, et al. Phase II trial of interleukin-2 and interferon alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response. J Immunother 1997;20:301-11.
23. Aebersold P, Hyatt C, Johnson S, et al. Lysis of autologous melanoma cells by tumour-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst 1991;83:932-7.
24. Molto L, Alvarez-Mon M, Carballido J, et al. Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. Br J Cancer 1994;70:1247-51.
25. Janssen RA, Buter J, Straatsman E, et al. HLA-DR expressing CD8-bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients. Cancer Immunol Immunother 1993;36:198-204.
26. Atzpodien J, Kirchner H, Korfer A, et al. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving subcutaneous interleukin-2 and interferon-alpha-2b. Tumour Biol 1993;14:354-9.
27. Zambello R, Trentin L, Cerutti A, et al. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells. Cancer 1994;74:2562-9.
28. Farace F, Angevin E, Dietrich P-Y, et al. Low-dose IL-2 treatment: activation of discrete T- and NK-cell sub-populations in vivo. Int J Cancer 1995;62:523-8.
29. Goedegebuure PS, Douville LM, Li H, et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 1995;13:1939-49.
30. Finke JH, Rayman P, Edinger M, et al. Characterization of human renal cell carcinoma specific cytotoxic CD8+ T cell line. J Immunother 1992;11:1-11.
31. Figlin RA, Pierce WC, Belldegrun A. Combination biologic therapy with interleukin-2 and interferon-alpha in the outpatient treatment of metastatic renal cell carcinoma. Semin Oncol 1993; 20(suppl 9): 11-5.
32. Molto L, Alvarez-Mon M, Carballido J, Olivier C, Gimeno F, Manzano L. Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer. Cancer 1995;75:2720-6.
33. Molto L, Carballido J, Manzano L, Reyes E, Olivier C, Alvarez-Mon M. The prophylactic intracavitary treatment with interferon alpha increases interferon gamma production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder. Br J Cancer 1997;75:1849-53.
34. Hayakawa K, Morita T, Augustus LB, von Eschenbaeh AC, Itoh K. Human renal-cell carcinoma cells are able to activate natural killer cells. Int J Cancer 1992;51:290-5.